Description: Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
Home Page: www.galeratx.com
GRTX Technical Analysis
2 West Liberty Boulevard
Malvern,
PA
19355
United States
Phone:
610 725 1500
Officers
| Name | Title |
|---|---|
| Dr. J. Mel Sorensen M.D. | CEO, Pres & Director |
| Mr. Christopher Degnan | Chief Financial Officer |
| Mr. Mark J. Bachleda M.B.A., Pharm.D. | Chief Commercial Officer |
| Dr. Robert A. Beardsley M.B.A., Ph.D. | Co-Founder & COO |
| Dr. Dennis P. Riley Ph.D. | Chief Scientific Officer, Emeritus |
| Ms. Jennifer Evans Stacey Esq. | Chief Legal & Compliance Officer and Sec. |
| Dr. Jon T. Holmlund M.D. | Exec. Officer |
| Ms. Andie Collier | Sr. VP of Regulatory Affairs |
| Ms. Judy Schnyder | Sr. VP of Clinical Operations & Data Management |
| Dr. Eugene P. Kennedy F.A.C.S., FACS, M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 29.3902 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-11-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 30 |